Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157
Tel: +81 (0)80-1164-4754
Request a Demo
What our customers are saying
When I think of the future, I think of EvaluatePharma
Global pharmaceutical company
Pharma and Biotech M&A Deals Reached Record $212 Billion in 2014
EP Vantage 2014 in Review report shows sector eclipsed $152 billion raised in 2009, the year of the mega merger
LONDON, BOSTON, TOKYO (March 19, 2015) — Despite a slight wobble in the spring, the pharma and biotech sector came back stronger than ever in 2014, racking up a record-breaking $212 billion in M&A transactions. The feel good factor also extended to IPOs. Largely fueled by investor appetite for immunotherapy, 2014 boasted 87 flotations, raising a combined $6.3 billion, one of the best hauls since the genomic bubble of 2000.
The venture capital funding environment also continued to improve, making 2014 one of the best years for the sector in living memory, according to the Pharma & Biotech 2014 in Review report published by EP Vantage, the editorial arm of market intelligence firm Evaluate.
Pharma & Biotech 2014 Year in Review Highlights:
- Specialty pharma M&A frenzy, including the $66 billion purchase of Allergan, helped drive the $212 billion in M&A transactions; eclipsing the $152 billion spent in 2009
- IPO filings doubled from 44 in 2013 to 87 in 2014; total amount raised jumped from $2.9 billion to $6.3 billion
- UK-based biopharma company, Circassia, broke IPO records with $332 million debut
- Venture capital funding rose by 33 percent to $6.5 billion
- FDA drug approvals rose 43 percent from 2013 with an impressive tally of 50 new drugs
- Eli Lilly was the best performing big pharma stock in 2014 with shares up 35 percent
- GlaxoSmithKline was the worst performing stock with shares down 15 percent in the year
“If people thought 2013 was a great year for the industry, 2014 defied logic and produced even better results with M&A activity reaching record highs, investors throwing money at the sector and the FDA approving a staggering 50 new drugs,” said Amy Brown, report author and EP Vantage reporter. “Early 2015 data indicate companies, bankers and venture capitalists have carried their appetite for the sector into the New Year. An estimated $3 billion was raised in January through secondary offerings alone. Whether this appetite is sustainable is another matter.”
The full version of the Pharma & Biotech 2014 in Review report, based on market intelligence from EvaluatePharma®, can be downloaded at www.evaluategroup.com/PharmaBiotech2014inReview.
About Evaluate Ltd.
Evaluate is the trusted source for life science market intelligence and analysis with exclusive consensus forecasts to 2020. We support life science and healthcare companies, financial institutions, consultancies and service providers in their strategic decision-making. Our services include EvaluatePharma, EvaluateClinical Trials and EvaluateMedTech. Our global team of dedicated healthcare analysts employs rigorous methodologies to deliver strategic commercial analysis. We make our services valuable by combining superior quality content, user-friendly reporting tools and outstanding customer service to solve client problems.
For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @epclinicaltrial, @epvantage, @evaluateJP.
Back to Press Releases